Literature DB >> 14968111

Modulation of p53 transcription regulatory activity and post-translational modification by hepatitis C virus core protein.

Chih-Fei Kao1, Shiow-Yi Chen, Jeou-Yuan Chen, Yan-Hwa Wu Lee.   

Abstract

Oncogenic virus proteins often target to tumor suppressor p53 during virus life cycle. In the case of hepatitis C virus (HCV) core protein, it has been shown to affect p53-dependent transcription. Here, we further characterized the in vitro and in vivo interactions between HCV core protein and p53 and showed that these two proteins colocalized in subnuclear granular structures and the perinuclear area. By use of a reporter assay, we observed that while low level of HCV core protein enhanced the transactivational activity of p53, high level of HCV core protein inhibited this activity. In both cases, however, HCV core protein increased the p53 DNA-binding affinity in gel retardation analyses, likely due to the hyperacetylation of p53 Lys(373) and Lys(382) residues. Additionally, HCV core protein, depending on its expression level, had differential effects on the Ser(15) phosphorylation of p53. Moreover, HCV core protein could rescue p53-mediated suppressive effects on both RNA polymerase I and III transcriptions. Collectively, our results indicate that HCV core protein targets to p53 pathway via at least three means: physical interaction, modulation of p53 gene regulatory activity and post-translational modification. This feature of HCV core protein, may potentially contribute to the HCV-associated pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14968111     DOI: 10.1038/sj.onc.1207368

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  40 in total

1.  Downregulation of Gadd45beta expression by hepatitis C virus leads to defective cell cycle arrest.

Authors:  Martin R Higgs; Hervé Lerat; Jean-Michel Pawlotsky
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

Review 2.  Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma.

Authors:  Amir Shlomai; Ype P de Jong; Charles M Rice
Journal:  Semin Cancer Biol       Date:  2014-01-20       Impact factor: 15.707

Review 3.  Hepatitis C-associated liver carcinogenesis: role of PML nuclear bodies.

Authors:  Kerstin Herzer; Guido Gerken; Thomas G Hofmann
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

Review 4.  Smad3 phospho-isoform signaling in hepatitis C virus-related chronic liver diseases.

Authors:  Takashi Yamaguchi; Katsunori Yoshida; Miki Murata; Koichi Matsuzaki
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

5.  Hepatitis C virus core protein and cellular protein HAX-1 promote 5-fluorouracil-mediated hepatocyte growth inhibition.

Authors:  Arup Banerjee; Kousuke Saito; Keith Meyer; Sutapa Banerjee; Malika Ait-Goughoulte; Ratna B Ray; Ranjit Ray
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

Review 6.  Hepatitis C virus infection and apoptosis.

Authors:  Richard Fischer; Thomas Baumert; Hubert-E Blum
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

7.  ANALYSIS OF HEPATITIS C VIRUS INFECTION MODELS WITH HEPATOCYTE HOMEOSTASIS.

Authors:  Timothy C Reluga; Harel Dahari; Alan S Perelson
Journal:  SIAM J Appl Math       Date:  2009-01-14       Impact factor: 2.080

Review 8.  Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer.

Authors:  David R McGivern; Stanley M Lemon
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

Review 9.  Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma.

Authors:  Alla Arzumanyan; Helena M G P V Reis; Mark A Feitelson
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

10.  Liver cancer-derived hepatitis C virus core proteins shift TGF-beta responses from tumor suppression to epithelial-mesenchymal transition.

Authors:  Serena Battaglia; Nassima Benzoubir; Soizic Nobilet; Pierre Charneau; Didier Samuel; Anna Linda Zignego; Azeddine Atfi; Christian Bréchot; Marie-Françoise Bourgeade
Journal:  PLoS One       Date:  2009-02-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.